Endocrinology Archives - Page 7 of 8 - Corcept Therapeutics

Evaluation of evidence of adrenal insufficiency in trials of normocortisolemic patients treated with mifepristone.

October 15, 2017

Yuen et al. • 2017 • J Endocr Soc. 2017;1(4):237-246.

U500 Insulin Screening of Diabetic Patients Uncovers a Large Amount of Undiagnosed Hypercortisolism Consistent With Cushing’s Syndrome

January 15, 2017

Editorial Team • 2017 • Diabetes

Mifepristone improves octreotide efficacy in resistant ectopic Cushing’s syndrome.

November 15, 2016

Moraitis AG, Auchus RJ. • 2016 • Case Rep Endocrinol. 2016;2016:8453801.

Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis

November 5, 2016

Steffensen et al • 2016 • European Journal of Endocrinology

Prevalence of subclinical hypercortisolism in type 2 diabetic patients from the Rio de Janeiro Type 2 Diabetes Cohort Study

October 15, 2016

Costa et al • 2016 • J Diabetes Complications.

Association between mifepristone dose, efficacy, and tolerability in patients with Cushing syndrome.

October 21, 2015

Yuen et al. • 2015 • Endocr Pract. 2015;21(10):1087-92.

Mifepristone and Cushing syndrome: A commentary.

October 15, 2015

Kennedy L. • 2015 • Endocr Pract. 2015;21(10):1175-7.

Long-Term Follow-Up in Adrenal Incidentalomas: An Italian Multicenter Study

November 15, 2014

Morelli et al • 2014 • J Clin Endocrinol Metab.

Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study

November 12, 2014

Di Dalmazi et al • 2014 • Lancet Diabetes Endocrinol.

Cortisol as a Marker for Increased Mortality in Patients with Incidental Adrenocortical Adenomas

November 10, 2014

Debono et al • 2014 • J Clin Endocrinol Metab.